BriaCell Therapeutics Stock Scheduled to Reverse Split on Wednesday, January 29th (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are scheduled to reverse split on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Stock Down 1.8 %

Shares of BriaCell Therapeutics stock opened at $0.38 on Tuesday. The business’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.74. The firm has a market cap of $16.71 million, a PE ratio of -0.42 and a beta of 1.55. BriaCell Therapeutics has a 52 week low of $0.37 and a 52 week high of $4.61.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). As a group, equities analysts expect that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.